Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Etelcalcetide (Parsabiv) Peptide
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
What is Etelcalcetide (Parsabiv)?
Etelcalcetide (Parsabiv) is a calcium-sensing receptor agonist · endocrine peptide studied for secondary hyperparathyroidism in adults on chronic hemodialysis. Below is an educational overview of Etelcalcetide (Parsabiv) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Parsabiv
Secondary hyperparathyroidism in adults on chronic hemodialysis.
An IV given at the end of dialysis that lowers high parathyroid hormone levels caused by kidney failure.
- •Low blood calcium (very common)
- •Muscle spasms
- •Diarrhea
- •Nausea
- •Vomiting
- •Symptomatic hypocalcemia (numbness, tetany, seizures, QT prolongation, arrhythmia)
- •Heart failure worsening
- •Upper GI bleeding (caution with risk factors)
- •Serum calcium below the lower limit of normal
- •Known hypersensitivity to etelcalcetide
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Etelcalcetide (Parsabiv) Mechanism of Action
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
Etelcalcetide (Parsabiv) Research Areas & Benefits
Etelcalcetide (Parsabiv) Dosage & Common Research Protocols
5 mg IV bolus at end of hemodialysis three times weekly; titrate.
Protocols summarized for educational reference from published research. Not dosing guidance.
Etelcalcetide (Parsabiv) Studies & Cited Research
Etelcalcetide vs cinacalcet
Non-inferior PTH reduction with IV administration.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Etelcalcetide (Parsabiv) Side Effects & Safety Considerations
- •FDA-approved.
- •Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.